190 related articles for article (PubMed ID: 29752463)
1. Personalization of prostate cancer therapy through phosphoproteomics.
Yang W; Freeman MR; Kyprianou N
Nat Rev Urol; 2018 Aug; 15(8):483-497. PubMed ID: 29752463
[TBL] [Abstract][Full Text] [Related]
2. Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine.
Wu X; Xing X; Dowlut D; Zeng Y; Liu J; Liu X
J Proteomics; 2019 Jan; 191():68-79. PubMed ID: 29621648
[TBL] [Abstract][Full Text] [Related]
3. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
4. Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection.
Labots M; van der Mijn JC; Beekhof R; Piersma SR; de Goeij-de Haas RR; Pham TV; Knol JC; Dekker H; van Grieken NCT; Verheul HMW; Jiménez CR
J Proteomics; 2017 Jun; 162():99-107. PubMed ID: 28442448
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtyping of cancer and nomination of kinase candidates for inhibition with phosphoproteomics: Reanalysis of CPTAC ovarian cancer.
Tong M; Yu C; Zhan D; Zhang M; Zhen B; Zhu W; Wang Y; Wu C; He F; Qin J; Li T
EBioMedicine; 2019 Feb; 40():305-317. PubMed ID: 30594550
[TBL] [Abstract][Full Text] [Related]
6. Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression.
Tonry C; Armstrong J; Pennington S
Oncotarget; 2017 Feb; 8(9):15307-15337. PubMed ID: 28410543
[TBL] [Abstract][Full Text] [Related]
7. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
[TBL] [Abstract][Full Text] [Related]
8. Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.
Ramroop JR; Stein MN; Drake JM
Front Oncol; 2018; 8():28. PubMed ID: 29503809
[TBL] [Abstract][Full Text] [Related]
9. Drug discovery in advanced prostate cancer: translating biology into therapy.
Yap TA; Smith AD; Ferraldeschi R; Al-Lazikani B; Workman P; de Bono JS
Nat Rev Drug Discov; 2016 Oct; 15(10):699-718. PubMed ID: 27444228
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
[TBL] [Abstract][Full Text] [Related]
11. Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression.
Tonry C; Armstrong J; Pennington SR
Oncotarget; 2017 Feb; 8(9):14374-14394. PubMed ID: 28086232
[TBL] [Abstract][Full Text] [Related]
12. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
[TBL] [Abstract][Full Text] [Related]
13. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
Drake JM; Graham NA; Lee JK; Stoyanova T; Faltermeier CM; Sud S; Titz B; Huang J; Pienta KJ; Graeber TG; Witte ON
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):E4762-9. PubMed ID: 24248375
[TBL] [Abstract][Full Text] [Related]
14. Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas.
Fordham AM; Ekert PG; Fleuren EDG
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188613. PubMed ID: 34390800
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
Drake JM; Paull EO; Graham NA; Lee JK; Smith BA; Titz B; Stoyanova T; Faltermeier CM; Uzunangelov V; Carlin DE; Fleming DT; Wong CK; Newton Y; Sudha S; Vashisht AA; Huang J; Wohlschlegel JA; Graeber TG; Witte ON; Stuart JM
Cell; 2016 Aug; 166(4):1041-1054. PubMed ID: 27499020
[TBL] [Abstract][Full Text] [Related]
16. Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.
Giacinti S; Poti G; Roberto M; Macrini S; Bassanelli M; DI Pietro F; Aschelter AM; Ceribelli A; Ruggeri EM; Marchetti P
Anticancer Res; 2018 Nov; 38(11):6029-6039. PubMed ID: 30396917
[TBL] [Abstract][Full Text] [Related]
17. TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression.
Baylot V; Karaki S; Rocchi P
Results Probl Cell Differ; 2017; 64():255-261. PubMed ID: 29149413
[TBL] [Abstract][Full Text] [Related]
18. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.
Oliveira-Barros EG; Nicolau-Neto P; Da Costa NM; Pinto LFR; Palumbo A; Nasciutti LE
Cell Biol Int; 2017 Nov; 41(11):1239-1245. PubMed ID: 28477422
[TBL] [Abstract][Full Text] [Related]
20. Implementation of Clinical Phosphoproteomics and Proteomics for Personalized Medicine.
Casado P; Hijazi M; Gerdes H; Cutillas PR
Methods Mol Biol; 2022; 2420():87-106. PubMed ID: 34905168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
